Cisplatin is one of the most used anticancer agents, and along with carboplatin and
oxaliplatin, is a part of more than 50% of clinically applied anticancer regimens [1]. However,
the side effects of cisplatin are severe and include dose-limiting toxicity, such as neurotoxicity,
nephrotoxicity and ototoxicity. Platinum(II) complexes with different structure from cisplatin
provide many opportunities for design of novel antitumor drugs with improved
pharmacological properties. Considering this, in the present study, new platinum(II) complexes
with phenothiazine (phtz) and N-methylphenothiazine (N-Mephtz), [PtCl2(phtz)(CH3CN)] (1)
and [PtCl2(N-Mephtz)(CH3CN)] (2), were synthesized. These complexes were characterized by
elemental microanalysis, NMR (1H and 13C) and IR spectroscopic measurements, while the
structure of complex 1 was determined by single-crystal X-ray diffraction analysis. The
antitumor activity of the platinum(II) complexes was tested in vitro against a panel of human
cancer cell lines, including A549 (lung cancer), A375 (melanoma, skin cancer), MDA-MB-231
(breast cancer), and HCT116 (colon cancer). To check the selectivity of the synthesized
complexes 1 and 2, a healthy MRC-5 cell line (lung fibroblasts) was also included in this study.Book of abstract:16th International Symposium
on Applied Bioinorganic Chemistry
(16-ISABC)
11-14th June
University of Ioannina
Greec
